1( NUMS 1) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 2) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 2) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
0( NUMS 1) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 2) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 2) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 2) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 2) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
1( NUMS 1) DOCPROPERTY prpGSDName\* MERGEFORMAT SOP-002 T02 Return Drug Request Form, ed DOCPROPERTY prpGSDVersion\* MERGEFORMAT 10 DOCPROPERTY prpGSDNo\* MERGEFORMAT Template Active Date: 16 Febr
尊敬的 费苛 院长:您好!由广东省临床试验协会申办的“吉非替尼对比长春瑞滨联合顺铂作为术后辅助治疗在病理证实为II-IIIA期(N1-N2)并存在EGFR敏感突变的非小细胞肺癌疗效的国内、多中心、随机、开放III期临床研究”的研究者发起的上市后药物临床试验,欲申请在我院开展进行:现请将以下研究相关文件转交贵院伦理委员会用于审阅:1首次保险201107252补充保险201110283
违法有害信息,请在下方选择原因提交举报